Last updated: February 16, 2026
Overview
NDC 68094-0909 is identified as Prolia (denosumab) 60 mg prefilled syringe. This drug is approved for osteoporosis treatment, bone metastases, and related conditions. Its market dynamics are influenced by competitive therapies, patent status, manufacturing costs, and regulatory landscape.
Market Size and Growth
The global osteoporosis market was valued at approximately $13.4 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 4.2% through 2028, reaching an estimated $18 billion. Denosumab holds a significant share, owing to its efficacy and dosing convenience.
In the U.S., the osteoporosis segment accounts for roughly $2.2 billion. Denosumab’s market share exceeds 60% among biologics prescribed for osteoporotic conditions. The drug’s approval for cancer-related indications, including bone metastases, extends its market reach further.
Pricing Landscape
-
Current U.S. List Price: The average wholesale price (AWP) for the 60 mg prefilled syringe ranges around $1,350 to $1,550 per dose. Actual negotiated payer prices are often lower due to discounts, rebates, and formulary arrangements.
-
Reimbursement: Medicare Part B and commercial insurers cover denosumab under joint payer arrangements. Patient out-of-pocket costs vary but are typically in the $40–$200 range, depending on deductibles and copay assistance programs.
-
Market Competition: Other anti-resorptive agents include bisphosphonates (e.g., alendronate, zoledronic acid) and newer agents such as romosozumab (Evenity). These alternatives can influence pricing pressures, especially for initial therapy.
Competitive and Regulatory Factors
-
Patent Life: The original patent expired in 2025 in the U.S., opening the pathway for biosimilars, which are expected to enter the market at lower prices within the next 1-3 years.
-
Biosimilar Impact: Biosimilars are projected to reduce list prices by 20-40%. Several biosimilars have received FDA approval; market entry timing remains critical.
-
Regulatory Hurdles: Post-approval patent challenges and biosimilar approval pathways influence the timeline and pricing strategies.
Price Projections (Next 5 Years)
| Year |
Expected List Price Range |
Underlying Factors |
| 2023 |
$1,400 – $1,600 |
Continuing demand, slight premiums for brand dominance |
| 2024 |
$1,300 – $1,500 |
Entry of biosimilars begins, slight price erosion |
| 2025 |
$1,200 – $1,400 |
Biosimilar launches, increased competition, patent cliff effect |
| 2026 |
$1,100 – $1,300 |
Market stabilization, increased biosimilar uptake |
| 2027 |
$1,000 – $1,200 |
Widespread biosimilar penetration, price competition |
Key Drivers
- Accelerated biosimilar adoption lowers prices.
- Payer negotiations and formulary management influence actual transaction prices.
- Expanded indications increase demand, supporting stable or slightly declining prices initially.
Risks and Opportunities
- Patent litigation can delay biosimilar entry, maintaining higher prices.
- Oral or alternative therapies under development pose long-term competitive risks.
- Biologics manufacturing costs may decline with technological improvements, leading to potential price decreases.
Summary
The current price for denosumab (NDC 68094-0909) is around $1,350–$1,550 per dose in the U.S. As biosimilars penetrate the market over the next three years, prices are expected to decline steadily, reaching approximately $1,000–$1,200 by 2027. Market growth remains balanced between sustained demand and competitive pressure from biosimilars and alternative therapies.
Key Takeaways
- NDC 68094-0909's current list price is approximately $1,400–$1,600 per dose.
- Market growth is driven by osteoporosis and cancer metastases indications, with strong competition from biosimilars.
- Price reductions of 20-40% are anticipated over the next 3 years, primarily due to biosimilar entry.
- Reimbursement and negotiation factors significantly impact net prices.
- Patent expiry in 2025 will accelerate biosimilar entry and price erosion.
FAQs
-
What is the primary driver of denosumab’s market valuation?
Its efficacy in osteoporosis and cancer-related bone conditions, combined with its convenient dosing schedule, sustains high market share.
-
How will biosimilar entry affect pricing?
Biosimilars are projected to decrease list prices by at least 20%, increasing market competition and reducing payer costs.
-
Are there alternative therapies that could impact denosumab’s market share?
Yes, oral bisphosphonates and newer agents like romosozumab may reduce demand, especially if cost savings are significant.
-
What is the typical out-of-pocket cost for patients?
Usually between $40 and $200, depending on insurance coverage and assistance programs.
-
What regulatory changes could influence future prices?
Approvals of biosimilars and potential patent litigations can affect market dynamics and pricing strategies.
Citations
- Market data sources, industry reports, and FDA approvals as of 2023.
- [1] EvaluatePharma: Osteoporosis market forecast 2022-2028.
- [2] FDA Biosimilar approvals and timelines.
- [3] Medicare and commercial insurance reimbursement policies.
